{"filings":[{"id":862518,"accession_number":"0001493152-26-027291","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2026-06-04T20:45:45+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bio Green Med Solution to acquire Future NRG; target shareholders to own >99% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock share exchange: Future NRG becomes wholly owned sub; pre-Exchange BGMS holders get <1% of combined entity.","Closing expected Q4 2026, subject to BGMS stockholder approval, Nasdaq listing, and SEC registration statement effectiveness.","Board to have 5 members: 4 current BGMS directors (minus Kiu Cu Seng who remains CFO) and 1 FNRG appointee.","Certain Selling Shareholders subject to 180-day lock-up on shares received in the exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443318,"accession_number":"0001493152-26-023117","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2026-05-14T20:25:36+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio Green Med Solution Q1 2026 net loss $0.2M, fire safety revenue $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.2M vs $0.1M in Q1 2025; prior year had $4.1M net income from discontinued ops.","Fire safety product revenue of $0.8M following Sep 2025 acquisition of Fitters Sdn. Bhd.","Cash and equivalents $3.3M, down from $3.5M; estimated to fund operations into Q4 2026.","G&A expenses fell ~$3.8M to $0.4M due to cost normalization after changes of control.","Trading of 6% Convertible Exchangeable Preferred Stock (BGMSP) suspended and delisted in March; $0.15/share dividend paid May 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91472,"accession_number":"0001493152-26-016325","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio Green Med Solution declares $0.15 quarterly dividend on 6% Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.15 per share declared on 6% Convertible Exchangeable Preferred Stock.","Payable May 1, 2026 to holders of record as of April 23, 2026.","Board of Directors approved the dividend on April 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101566,"accession_number":"0001493152-26-013611","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio Green Med Solution narrows 2025 net loss to $3.0M; records $0.7M fire safety revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2025 was $3.0M vs $11.2M in 2024; Q4 net loss of $0.6M vs $3.0M.","Product revenue from fire safety equipment (Fitters acquisition) $0.7M in both Q4 and FY 2025.","Cash and equivalents $3.5M at Dec 31, 2025; cash runway estimated into Q3 2026.","Sold plogosertib assets in Oct 2025 for $300K plus $170K milestone; UK sub liquidated Jan 2025.","Declared Q1 2026 preferred dividend of $0.15/share on 6% convertible preferred, paid Feb 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101565,"accession_number":"0001493152-26-009991","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bio Green Med preferred stock (BGMSP) to be delisted from Nasdaq for MVPHS non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BGMSP fails to maintain $1M minimum market value of publicly held shares; will delist.","Company will not appeal; delisting expected on or after April 2, 2026.","Trading of BGMSP suspended at open March 23, 2026; may move to OTC Markets.","Common stock (BGMS) remains listed on Nasdaq Capital Market and is unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101564,"accession_number":"0001493152-26-001848","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio Green Med declares $0.15/share quarterly dividend on Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared $0.15 per share cash dividend on 6% Convertible Exchangeable Preferred Stock (BGMSP).","Dividend payable on February 1, 2026, to holders of record as of January 22, 2026.","Declaration made on January 12, 2026, in ordinary course."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117904,"accession_number":"0001493152-25-022378","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio Green Med Solution Q3 net loss $1.0M; revenue begins from fire safety; Fitters acquisition closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.0M for Q3 2025, halved from $2.0M in Q3 2024; cash $3.8M at Sept 30, 2025.","First product revenue from fire safety equipment: $81,000; cost of sales $64,000.","Completed acquisition of Fitters Sdn. Bhd. on Sept 12, 2025 for 19.99% of BGMS common stock.","Sold Plogosertib oncology assets for $300,000 cash plus up to $170,000 milestone payment.","Declared $0.15 quarterly dividend on 6% Convertible Exchangeable Preferred Stock, paid Nov 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":81000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117903,"accession_number":"0001493152-25-020920","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bio Green Med exchanges 1.4M warrants for common stock under Section 3(a)(9) exemption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate of 1,402,605 shares of common stock issued in exchange for Series A, B, and C warrants originally issued in June 2025.","Exchange relies on Section 3(a)(9) exemption; new shares are unrestricted.","Beneficial ownership limitation of 9.99% of outstanding common stock after issuance.","Example: one holder exchanged 467,535 warrants for an equal number of shares.","Exchanged warrants are cancelled upon transfer to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117902,"accession_number":"0001493152-25-017224","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio Green Med declares $0.15 quarterly dividend on preferred stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.15 per share on 6% Convertible Exchangeable Preferred Stock.","Payable November 1, 2025 to holders of record as of October 20, 2025.","Dividend declared by Board of Directors on October 7, 2025.","Preferred stock trades under ticker BGMSP on Nasdaq; common stock trades as BGMS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117901,"accession_number":"0001493152-25-017223","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Bio Green Med Solution sells Plogosertib assets to Tethra Biosciences for $300K upfront plus $170K milestone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold all patent rights and IP related to Plogosertib (PLK1 inhibitor) to Tethra Biosciences Inc.","Total consideration: $300,000 upfront plus a potential $170,000 milestone upon first patient dosing in Phase 2.","Transaction closed on October 6, 2025, with customary representations and warranties.","Buyer assumes obligations related to the Compound from closing forward; seller retains excluded liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134353,"accession_number":"0001493152-25-014840","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio Green Med appoints Zara Pappas to board after Kwang Fock Chong resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kwang Fock Chong resigned as independent director on Sept 19, 2025; no disagreement with the company.","Soon Ping \"Zara\" Pappas appointed effective Sept 23, 2025; will receive $1,000/month.","Pappas appointed to Audit, Compensation, and Nominating committees; chairs Compensation committee.","Board now has 5 directors, 3 independent, complying with Nasdaq Listing Rule 5605(b)(1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134351,"accession_number":"0001493152-25-013902","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K/A","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio Green Med Solution files 8-K/A to correct logo on cover page; no substantive changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment filed solely to replace incorrect logo on cover page of Sept 12, 2025 Original 8-K.","Original 8-K announced name change to Bio Green Med Solution and ticker symbols BGMS/BGMSP.","No financial or operational changes made; logo correction is administrative only.","CEO Datuk Dr. Doris Wong Sing Ee executed the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134352,"accession_number":"0001493152-25-013703","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bio Green Med receives Nasdaq deficiency notice for preferred stock (BGMSP) over minimum MVPHS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified that BGMSP's Market Value of Publicly Held Shares fell below $1M for 30 consecutive business days.","Company has 180 days until March 10, 2026 to regain compliance by achieving MVPHS of at least $1M for 10 consecutive days.","Deficiency does not affect common stock (BGMS) listing; preferred stock continues to trade during cure period.","Company will evaluate options if compliance not regained, including potential delisting and Nasdaq appeal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134364,"accession_number":"0001493152-25-013123","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["2.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Bio Green Med (f/k/a Cyclacel) closes acquisition of Fitters Sdn. Bhd. for 699,158 shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued 699,158 common shares (19.99% ownership) to FITTERS Diversified Berhad for 100% of Fitters Sdn. Bhd.","Company renamed Bio Green Med Solution, Inc.; tickers changed to BGMS and BGMSP on Nasdaq.","Fitters, a Malaysia-based fire safety equipment distributor, had Q2 2025 revenue of $501K and net loss of $47K.","Pro forma combined net loss for Q2 2025: $1.28M; for FY2024: $11.3M; goodwill of $428K recognized.","Company now operates in fire protection and biopharmaceutical industries, headquartered in Kuala Lumpur."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134363,"accession_number":"0001641172-25-026676","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders approve stock issuance to Fitters Parent and name change to Bio Green Med Solution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to approve stock issuance to Fitters Parent passed with 58.8% of votes for (1,095,988 shares).","Proposal for >20% stock issuance in connection with Transaction under Nasdaq Rule 5635(a) also passed (58.8% for).","Amendment to charter changing corporate name to Bio Green Med Solution, Inc. approved (58.9% for).","All three proposals approved at Special Meeting on September 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.15,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134362,"accession_number":"0001641172-25-026571","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Cyclacel exchanges 559,395 Series C warrants for common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 559,395 Series C warrants for 559,395 shares of common stock under Section 3(a)(9) exemption.","Warrants issued June 20, 2025; exchange reduces potential dilution by canceling warrants.","Each holder example: 186,465 warrants exchanged for 186,465 shares; 31,535 warrants remain.","New shares unrestricted; no cash proceeds to company.","Transaction closed September 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134361,"accession_number":"0001641172-25-026110","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cyclacel removes ownership limit on Series A, B, C warrants, allowing full exercise of up to 654K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended warrants remove 4.99% Ownership Limitation on exercise and voting, effective September 1, 2025.","Series A: 218K shares at $7.65; Series B: 218K at $9.00; Series C: 218K at $10.20, all expiring 5 years from issuance.","Board and majority stockholder approved removal as disclosed in July 2025 Schedule 14C.","No other terms of the warrants changed; cashless exercise provision remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134360,"accession_number":"0001641172-25-025752","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Cyclacel dismisses auditor Bush & Associates; going concern doubt flagged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Bush & Associates CPA LLP as independent auditor effective August 22, 2025.","Engaged SFAI Malaysia PLT as new independent registered public accounting firm for fiscal year 2025.","Bush advised the Company lacks sufficient funds to complete development and commercialization, raising substantial doubt about going concern.","No disagreements or reportable events occurred except the going concern matter; Company authorized Bush to respond to SFAI inquiries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134359,"accession_number":"0001641172-25-023607","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cyclacel Q2 net loss $1.3M; cash $4.3M; share exchange with FITTERS on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.3M (incl. $7K stock comp) vs $3.3M in Q2 2024; revenue not reported.","Cash and equivalents $4.3M at June 30, 2025, estimated to fund into Q4 2025.","R&D expenses dropped to $0.1M from $2.0M after UK subsidiary liquidation in Jan 2025.","Agreed share exchange: FITTERS will exchange 100% of FITTERS Sdn. Bhd. for ~19.99% of CYCC common stock; $1M cash added; special meeting Sep 4, 2025.","In July, one-for-15 reverse stock split to meet Nasdaq bid price; $3M Series F convertible preferred raised in June."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134358,"accession_number":"0001641172-25-023296","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Cyclacel faces going concern warning; cash of $3.45M expected only into Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Auditor expresses substantial doubt about Cyclacel's ability to continue as a going concern; cash of $3.45M at March 31, 2025, expected to fund only into Q2 2025.","Net loss of $81k for Q1 2025 vs $2.9M in Q1 2024, largely due to a $4.9M gain from deconsolidation of UK subsidiary Cyclacel Limited on Jan 24, 2025.","Operating loss of $5.0M; R&D expenses fell to $822k from $2.8M, while G&A rose to $4.2M from $1.6M, partly due to $1.7M stock-based compensation.","Issued Series D and E preferred stock and converted shares; common shares outstanding surged from 8.9M to 207.3M during Q1 2025.","Regained Nasdaq compliance with equity rule on Feb 25, 2025; subject to one-year mandatory panel monitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134357,"accession_number":"0001641172-25-021159","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cyclacel removes ownership limitation on Series F Convertible Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Amended Certificate of Designation removing Series F Ownership Limitation that capped conversion/voting at 4.99% of common stock.","Effective July 28, 2025, after board and majority stockholder approval per Schedule 14C filed July 7, 2025.","No other changes to Series F Convertible Preferred terms; removal allows unrestricted conversion and voting.","Potential for increased dilution if holders convert shares without prior ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134356,"accession_number":"0001641172-25-019834","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclacel Pharmaceuticals comments on recent stock price volatility, unaware of material changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 15, 2025, Cyclacel's stock experienced significant volume and price movements.","The Company stated it is not aware of any material developments or changes to its operating or financial condition.","Cyclacel previously announced an amendment to the Exchange Agreement with FITTERS Diversified Berhad on July 7, 2025.","The Company issued a press release on July 16, 2025 commenting on the volatility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134355,"accession_number":"0001641172-25-017906","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclacel amends exchange deal with FITTERS: adds $1M cash, extends closing to Sept 30","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment adds $1M cash consideration (or mutually agreed amount) to the existing stock-based consideration for FITTERS.","Final closing date extended from original to September 30, 2025.","Transaction exchanges all ordinary shares of Fitters Sdn. Bhd. for 19.99% of Cyclacel common stock (subject to adjustment).","Deal still requires stockholder approval from Cyclacel and FITTERS; Boards have approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134354,"accession_number":"0001641172-25-017479","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Cyclacel implements 1-for-15 reverse stock split effective July 7, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:15 ratio, effective July 7, 2025; trading begins split-adjusted that day.","Pre-split shares outstanding: 23,759,475; post-split: approx. 1,583,965 shares.","Split approved by board and stockholders; aims to meet Nasdaq minimum bid price requirement.","No fractional shares; rounding up or down to the nearest whole share.","New CUSIP 23254L876; ticker remains CYCC on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151175,"accession_number":"0001641172-25-017152","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cyclacel shareholders reelect directors, approve equity plan increase, endorse executive pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected all five director nominees with over 99.97% support each.","Approved amendment to 2018 Equity Incentive Plan increasing share reserve by 4,281,987 shares (99.94% votes for).","Advisory vote on executive compensation passed with 99.95% votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151174,"accession_number":"0001641172-25-015874","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.02","1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Cyclacel raises $3M via convertible preferred stock and warrants; cash runway into Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.0M from sale of 3M shares of Series F Convertible Preferred at $1.00 per share.","Each preferred share converts into 3.27 common shares; conversion requires stockholder approval per Nasdaq rules.","Issued 29.43M warrants (Series A/B/C) at exercise prices $0.51, $0.60, $0.68, all expiring in 5 years.","Net proceeds for working capital; combined with existing cash expected to fund operations into Q3 2025.","Offering sold under Regulation S to non-U.S. accredited investors without a placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151173,"accession_number":"0001641172-25-013479","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclacel declares $0.15/share quarterly dividend on 6% Convertible Exchangeable Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.15 per share on Preferred Stock (CYCCP) declared on June 3, 2025.","Payable on August 1, 2025 to holders of record as of July 21, 2025.","Preferred stock carries 6% convertible exchangeable terms; common stock (CYCC) unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151172,"accession_number":"0001641172-25-013436","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cyclacel regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Compliance Notice dated June 3, 2025 confirming compliance with Listing Rule 5550(a)(2).","Closing bid price exceeded $1.00 for 15 consecutive business days from May 12 to June 2, 2025.","Company had previously received a non-compliance notice on December 6, 2024.","Nasdaq confirmed the matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151171,"accession_number":"0001641172-25-010873","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclacel Pharmaceuticals Q1 2025: Deconsolidation Gain, FITTERS Exchange, Focus on Plogosertib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cyclacel reported Q1 2025 net loss of $0.1 million, compared to $2.9 million in Q1 2024.","Deconsolidation of UK subsidiary Cyclacel Limited resulted in a $5.0 million gain on deconsolidation.","Company repurchased plogosertib assets from Cyclacel Limited for approximately $0.3 million.","Entered into an Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd. for 19.99% of common stock.","Cash and cash equivalents totaled $3.5 million as of March 31, 2025, expected to fund into Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151170,"accession_number":"0001641172-25-008988","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Cyclacel announces 1-for-16 reverse stock split effective May 12, 2025 to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-16; effective May 12, 2025 at market open.","Pre-split shares: 356,357,531; post-split shares: 22,272,346 (rounded).","No fractional shares; rounding rules apply for shares half or more/less than half.","CUSIP changes to 23254L884; trading symbol remains CYCC on Nasdaq Capital Market.","Split approved by board and stockholders to regain compliance with Nasdaq minimum bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151169,"accession_number":"0001641172-25-008836","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclacel enters share exchange to acquire Fitters Sdn. Bhd.; existing holders to own 80%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cyclacel to exchange 19.99% of its common stock for 100% of Fitters Sdn. Bhd.","Existing Cyclacel stockholders expected to own ~80.01% of combined company post-closing.","Company to be renamed Bio Green Med Solution, Inc., trading on Nasdaq under new ticker.","Fitters Sdn. Bhd. operates fire safety, waste-to-resource, and real estate development.","Closing deadline set for August 31, 2025; mutual termination right after that date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151168,"accession_number":"0001641172-25-006201","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cyclacel increases authorized common shares from 250M to 600M; removes Series E conversion cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board and majority stockholder approved Certificate of Amendment filed April 25, 2025.","Authorized common stock increased from 250,000,000 to 600,000,000 shares; no change to issued shares.","Amended Series E Certificate of Designation removes the 4.99% ownership limitation on conversion and voting.","Removal of Series E cap allows unlimited conversion of preferred into common shares going forward.","Both amendments effective upon filing with Delaware Secretary of State on April 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151167,"accession_number":"0001641172-25-005476","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclacel declares $0.15 quarterly dividend on 6% Convertible Exchangeable Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Cash dividend of $0.15 per share on CYCCP (6% Convertible Exchangeable Preferred Stock).","Payable May 1, 2025 to holders of record as of April 29, 2025.","Board determined surplus and performed financial analysis; future dividends not assured.","No dividend declared on common stock (CYCC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151166,"accession_number":"0001829126-25-002334","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Cyclacel reports Q4 net loss $3.0M; pro forma cash $7.2M; deconsolidates unit; board appointments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.0M for Q4 2024 and $11.2M for full year; cash of $3.1M at Dec 31, 2024.","Pro forma cash $7.2M including $4.1M equity financing post-quarter; cash runway into Q2 2025.","Focusing on plogosertib (PLK1 inhibitor) acquired from Cyclacel Ltd; new oral formulation in development.","Deconsolidation of Cyclacel Ltd expected to increase equity by ~$5.0M and significantly reduce R&D spend.","Two new independent directors appointed: Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan; committee chairs set."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170069,"accession_number":"0001829126-25-002001","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["3.02","1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Cyclacel raises $1M via Series E convertible preferred stock; extends cash runway to Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.0M from sale of 1M shares of Series E Convertible Preferred Stock at $1.00 per share.","Each Series E share convertible into 110 common shares, subject to stockholder approval per Nasdaq rules.","Offering closed on March 21, 2025; net proceeds for working capital and general corporate purposes.","Cash runway extended into third quarter 2025 based on current operating assumptions.","Securities sold under Regulation S exemption, no placement agent used."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170068,"accession_number":"0001829126-25-001770","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Cyclacel acquires Plogosertib assets from liquidated subsidiary for £250K","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cyclacel Pharmaceuticals buys PLK1 inhibitor Plogosertib assets from wholly-owned UK subsidiary in liquidation for £250,000.","Includes patent rights, API, CMC data, preclinical and clinical data, and know-how related to Plogosertib.","Buyer agrees to only sell assets for cash consideration within 24 months; any surplus (50% of net proceeds) paid to subsidiary.","Transaction closed on March 10, 2025; Patent Assignment Agreement also executed.","Debt/liabilities of seller not assumed; buyer responsible for subsequent disposal surplus payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170067,"accession_number":"0001829126-25-001253","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","5.02","3.01","3.03","5.01","9.01"],"status":"ready","headline":"Cyclacel changes control; new majority owner holds 70% and appoints new CEO and CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Datuk Dr. Doris Wong Sing Ee bought 1M Series C and 1.745M Series D shares from ex-interim CEO David Lazar for $6.3M, gaining 70% ownership.","Preferred shares converted into 194.63M common shares, making Wong the controlling shareholder.","David Lazar resigned as interim CEO; Datuk Dr. Doris Wong Sing Ee appointed CEO and director; Kiu Cu Seng appointed CFO, executive director, secretary.","Five directors resigned, including Samuel Barker, Paul McBarron, Spiro Rombotis; new independent director Chong Kwang Fock appointed.","Nasdaq compliance regained for equity rule; company subject to one-year Mandatory Panel Monitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170066,"accession_number":"0001829126-25-001180","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cyclacel amends stock purchase agreement with interim CEO for up to $8M equity line; adds 6-month lock-up","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price amended to greater of closing bid at signing or prior to each purchase date.","Added 6-month lock-up on any Shares issued under the agreement.","Company retains right to direct David Lazar to buy up to $8,000,000 of common stock through Sep 30, 2026.","Shares issued in reliance on exemptions under Securities Act Section 4(a)(2) and Regulation S or D.","Lazar is interim CEO; lock-up applies for six months from issuance date of each tranche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170065,"accession_number":"0001829126-25-000905","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Cyclacel removes preferred stock ownership caps and increases authorized shares to 250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders removed Series C and D convertible preferred stock ownership limitations, eliminating conversion caps.","Authorized common shares increased from 100M to 250M; charter amendment filed Feb 10, 2025.","David Lazar received 2.1M Series D preferred shares after Series D amendment removal of the 49.99% cap.","Series C amendment removed 5% ownership limit; Series D removed 49.99% limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170064,"accession_number":"0001829126-25-000765","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","5.07","3.02","8.01","9.01"],"status":"ready","headline":"Cyclacel raises up to $33M via Lazar & Helena equity lines; stockholders approve reverse split and share increases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lazar purchase agreement: up to $8M in Common Stock, exercisable by company until Sept 30, 2026, in $1M/$2M increments.","Helena equity line: up to $25M over 36 months; initial commitment shares $125K; purchases at 95% of VWAP, min stock price $0.20.","Amended Armistice exchange: $1.1M cash deferred to Q1 2025 filing; additional 100,000 shares issued subject to stockholder approval (received).","Stockholders approved reverse stock split (1:4 to 1:16), authorized shares increase to 250M, and issuances to Lazar and Armistice.","Company believes it has regained Nasdaq minimum stockholders' equity of $2.5M after these transactions and Cyclacel Ltd. deconsolidation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170063,"accession_number":"0001829126-25-000729","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclacel places UK subsidiary into CVL; to buy plogosertib, sell fadraciclib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UK subsidiary Cyclacel Ltd entered creditors voluntary liquidation; joint liquidators appointed.","Company plans to purchase plogosertib from liquidators for new oral formulation development.","Fadraciclib program will be marketed for sale by liquidators and removed from company assets.","Deconsolidation expected to increase stockholders' equity by approximately $5.6M in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170062,"accession_number":"0001104659-25-002198","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Cyclacel corrects board appointment error in Securities Purchase Agreement with David Lazar","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Addendum corrects inadvertent error: Mr. Lazar was not appointed as Board member or Chairman, only has right to appoint one director.","David Natan appointed as designee of Lazar and chairman of audit committee.","Amendment restates Section 2.3(a)(v) to reflect correct intent regarding board appointment and resolutions.","All other terms of the Purchase Agreement remain unchanged and in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170061,"accession_number":"0001104659-25-001087","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","3.02","1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Cyclacel: $3.1M private placement, CEO resigns, Lazar appointed interim CEO, board revamp, warrant exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David E. Lazar invests $3.1M for 1M Series C (convertible at 2.65:1) and 2.1M Series D (110:1) preferred shares.","CEO Spiro Rombotis resigns; David Lazar appointed interim CEO; five directors resign, replaced by Natan and Ben-Tzvi.","Company exchanges 24.8M warrants for 24.8M common shares plus $1.1M cash from an institutional holder.","Special meeting by Feb 15, 2025 to vote on stock issuance, reverse split (1:4-1:16), authorized shares to 250M, equity plan increase.","Proceeds used to repay liabilities and for general corporate purposes; cash must support at least three months post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187080,"accession_number":"0001104659-24-128022","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cyclacel receives Nasdaq bid-price deficiency notice; stock at risk of delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Cyclacel on Dec 6, 2024, that common stock bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until June 4, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by June 4, 2025, Nasdaq may delist common stock; company may appeal to hearings panel.","Cyclacel is considering alternatives including a potential reverse stock split to meet the bid-price rule.","Common stock continues trading on Nasdaq under symbol CYCC during the grace period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187079,"accession_number":"0001104659-24-119469","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Cyclacel raises $2.1M via warrant exercise, issues new warrants for ~19.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.1M from cash exercise of 4,968,945 Series B warrants at reduced price $0.415/share.","Holder received new Series C warrants (9,937,890 shares) and Series D warrants (9,937,890 shares) exercisable at $0.415 after stockholder approval.","Placement agent H.C. Wainwright received PA warrants for 298,137 shares at $0.5188/share plus 7% cash fee.","Net proceeds intended for working capital and general corporate purposes.","New warrants unregistered; resale registration statement to be filed within 30 days of agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187078,"accession_number":"0001104659-24-116903","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclacel Q3 net loss $2.0M, cash $3.0M; Nasdaq extension to Dec 24; going concern doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.0M for Q3 2024 vs $6.0M a year ago; cash $3.0M as of Sept 30, 2024.","R&D expenses fell to $1.0M from $5.2M; fadraciclib R&D $0.9M vs $3.6M.","Nasdaq granted extension to Dec 24, 2024 to regain minimum stockholders' equity compliance.","Substantial doubt about going concern; may curtail operations or file for bankruptcy if funding not secured.","Initial safety/efficacy data from 12 patients in fadraciclib Phase 2 cohort presented at Triple Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":-490.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":43000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187077,"accession_number":"0001104659-24-116875","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Cyclacel dismisses auditor Crowe over warrant equity classification issue; engages Bush & Associates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Crowe LLP as auditor Nov 5, 2024; Crowe was engaged Aug 19, 2024.","Crowe flagged warrant provisions in April 2024 and prior SPA may preclude equity classification, potentially impacting financial statements.","No disagreements on accounting principles; reportable event not yet discussed with Audit Committee.","New auditor Bush & Associates CPA LLP engaged for FYE Dec 31, 2024, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187076,"accession_number":"0001104659-24-111145","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Cyclacel gets Nasdaq extension to Dec 24, 2024 to meet equity minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearing Panel granted until Dec 24, 2024 to regain compliance with Rule 5550(b)(1).","Company had stockholders' equity below $2.5 million as of June 30, 2024.","No assurance compliance will be met; delisting risk remains if not regained by deadline.","Listing Council may review panel decision within 45 days of Oct 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203603,"accession_number":"0001104659-24-097731","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclacel suspends quarterly cash dividend on 6% Convertible Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board resolved on Sept 4, 2024 to suspend Nov 1, 2024 quarterly dividend on Preferred Stock (CYCCP).","Future dividend payments will be evaluated on a quarterly basis by the Board.","Preferred stock carries 6% convertible exchangeable terms; suspension may signal liquidity concerns.","No change to common stock dividend (if any) or other obligations mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203602,"accession_number":"0001104659-24-095276","cik":1130166,"company_name":"Bio Green Med Solution, Inc.","ticker":"BGMS","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cyclacel receives Nasdaq delisting notice for equity deficiency; hearing set for Oct 15, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff determined Cyclacel's stockholders' equity was below $2.5M as of June 30, 2024, violating Listing Rule 5550(b)(1).","Company requested a hearing before Nasdaq Hearings Panel, automatically staying any suspension or delisting pending decision.","Hearing scheduled for October 15, 2024; company will present plan to regain compliance with equity rule.","No assurance that hearing will be successful or that company can maintain compliance if listing continues.","If appeal denied or compliance not regained, common and preferred stock subject to delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5298677.7202072535,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-30T23:59:59+00:00|203602"}